RankAlpha logo
Back to Rankings

APGE

Apogee TherapeuticsC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
The strongest outcome is timely AbbVie closing near the $135.11 cash consideration, with positive APEX data and planned Phase 3 execution supporting deal certainty and limiting break risk.
Posture
Mixed
Lead driver
Sentiment
What changed
4 setup hits (3d) with net bullish as of 2026-09-08.
What can break
AbbVie transaction remains subject to shareholder approval and required regulatory approvals.
Momentum
64
Value
41
Sentiment
61
Setup hits (3d)
4 · Net Bullish
AI TargetsBase $135.11 · Bull $138.00 · Bear $95.00Analysis 2026-08-13; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-13 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-09-09

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions

Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Bullish
Target $137.58
Why
Momentum64 · Δ7d -5.2
Value41 · Δ7d 0.0
Sentiment61 · Δ7d -3.5
So what
Balanced signals (Net Bullish). Wait for confirmation before sizing up.

Confirming evidence

  • • 4 setup hits (3d) with net bullish as of 2026-09-08.
  • • Sentiment remains the lead driver in the composite, 7D delta -3.5.

Contradictions & invalidation

  • • AbbVie transaction remains subject to shareholder approval and required regulatory approvals.
  • • Anticipated director resignations may create governance or execution-transition risk, although the filing says they are not due to operational disagreement. [#8-K-2026-08-11]
  • • The principal downside is transaction failure or delay, after which APGE would again be valued as a clinical-stage biotech exposed to Phase 3, regulatory, safety, and execution uncertainty.

Catalyst clock

2026-08-10

Q2 update confirms APEX progress

Lead driver: Sentiment · See AI snapshot
Momentum
64
9% active weight
Current posture
7d trendFlat
Δ7d
-5.2
Δ21d
-33.4
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
61
62% active weight
Current posture
7d trendSoftening
Δ7d
-3.5
Δ21d
-2.5
Why this grade

Composite grade C. Momentum 64.5 / Value 41.2 / Sentiment 61.2

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-13. Scenario method

B+
Bull case
5%
Probability
Target price
$138.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
Most likely
B
Base case
88%
Probability
Target price
$135.11
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
B-
Bear case
7%
Probability
Target price
$95.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$10.19B
Beta
-
Shares Out
75.69M
P/E (TTM) · Derived
-31.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-36.14
Rev YoY
-
EPS YoY
+0.6%
Gross Margin
-
Op Margin
-
Net Debt
-$721.34M
Current Ratio
26.44
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data